nach oben

Erschienen in:

01.12.2018 | Clinical study

Higher than expected ADR rates with immune checkpoint inhibitors

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

Data from a large US-based population with non-small cell lung cancer (NSCLC) show that the rates of ADRs with immune checkpoint inhibitors (ICIs) may be higher than initially reported.803360171 …

, et al. Higher than expected ADR rates with immune checkpoint inhibitors. Reactions Weekly : No. 1730, 1 Dec 2018

Cathcart-Rake EJ, et al. Immunotherapy-related toxicities: More common than originally reported? Internet Document : 17 Nov 2018. Available from: URL: https://meetinglibrary.asco.org/record/167317/abstract

American Society of Clinical Oncology (ASCO). Side Effects From Certain Immunotherapies May Be Higher Than Initially Reported. Internet Document : 13 Nov 2018. Available from: URL: https://www.asco.org/about-asco/press-center/news-releases/side-effects-certain-immunotherapies-may-be-higher-initially

Titel: Higher than expected ADR rates with immune checkpoint inhibitors
Publikationsdatum: 01.12.2018
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-018-54911-7

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Higher than expected ADR rates with immune checkpoint inhibitors

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Aciclovir

Antibacterials

Gadoterate meglumine

Valproic acid

Post-approval studies in US are "vital to enhancing patient safety"

Cobimetinib